Epilepsy comprises several syndromes, amongst the most common being mesial temporal lobe epilepsy with hippocampal sclerosis. Seizures in mesial temporal lobe epilepsy with hippocampal sclerosis are typically drug-resistant, and mesial temporal lobe epilepsy with hippocampal sclerosis is frequently associated with important co-morbidities, mandating the search for better understanding and treatment. The cause of mesial temporal lobe epilepsy with hippocampal sclerosis is unknown, but there is an association with childhood febrile seizures. Several rarer epilepsies featuring febrile seizures are caused by mutations in SCN1A, which encodes a brain-expressed sodium channel subunit targeted by many anti-epileptic drugs. We undertook a genome-wide association study in 1018 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 7552 control subjects, with validation in an independent sample set comprising 959 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 3591 control subjects. To dissect out variants related to a history of febrile seizures, we tested cases with mesial temporal lobe epilepsy with hippocampal sclerosis with (overall n = 757) and without (overall n = 803) a history of febrile seizures. Meta-analysis revealed a genome-wide significant association for mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures at the sodium channel gene cluster on chromosome 2q24.3 [rs7587026, within an intron of the SCN1A gene, P = 3.36 x 10 -9 , odds ratio (A) = 1.42, 95% confidence interval: 1.26-1.59]. In a cohort of 172 individuals with febrile seizures, who did not develop epilepsy during prospective follow-up to age 13 years, and 6456 controls, no association was found for rs7587026 and febrile seizures. These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.
SCN1A and Febrile Seizures in Mesial Temporal Epilepsy: An Early Signal to Guide Prognosis and Treatment?
some 2q24 that includes SCN2A and SCN3A (5) . SCN1A encodes a voltage-gated sodium channel alpha subunit. The alpha subunit of sodium channels forms the membrane pore. Each alpha subunit protein has four domains with six transmembrane segments connected by loops. The majority of SCN1A mutations cluster in the C-terminus and the pore loops in the first three domains of the protein (5, 10) . The pathophysiology of SCN1A mutations is a decrease in the activity of GABAergic inhibitory neurons. For example, most of the mutations that cause Dravet syndrome (SMEI) result in loss of function, whereas mutations that cause GEFS+ are missense, likely altering channel activity (3) . However, about 5% of individuals with mutation-positive SMEI have a familial missense SCN1A mutation associated with a milder phenotype (i.e., GEFS+) in other family members (5) .
The study by Kasperaviciute et al., is a multicenter, multinational genetic association study involving a large cohort of subjects with MTS with and without a history of FS. The aim of this study was to identify an association, if not a mechanism, of the most common focal-onset epilepsy when associated with early FS. A detailed meta-analysis demonstrated a target at the sodium channel gene cluster on chromosome 2q24.3 (rs7587026, within an intron of the SCN1A gene). Those subjects with early FS followed to nearly age 15 without developing hippocampal sclerosis HS did not possess the mutation. Although this study does not explain whether FS cause MTS, or whether pre-existing hippocampal abnormalities predispose to FS (2), it suggests that patients with MTS, with or without a history of FS possess different underlying pathogenetic mechanisms.
The study controls for the specificity of the association for MTS + FS rather than FS alone, since developing epilepsy following a history of FS is most often apparent by age 15 (4) . No association of the rs7587026 with FS where patients did not develop epilepsy was found in comparison with controls from the same cohort. The authors reported observing a signal in MTS + FS not due to a history of FS alone. In addition, a dissociation was demonstrated where no significant relationship was detected in a group of patients with other partial epilepsies and a history of FS. The authors reported that their genetic association strategy did not differentiate between cell types (interneurons as proposed in Dravet syndrome vs principal neurons). Additionally, the authors did not address possible mechanisms underlying the specificity of hippocampal pathophysiology, or insight as to the critical age range of onset. Translational implications of this study include developing potential pharmacogenetic testing as a tool for individualized therapy. For example, mutations in the alpha-unit of the SCN1A gene have been associated with decreased efficacy of sodium channel blocking anti-epileptic medications. A single nucleotide polymorphism in SCN1A is associated with carbamazepine-resistant epilepsy. As a result, such individu-als require higher maintenance dose of carbamazepine (9) . Of note, children with SCN1A-related epilepsy may be at high risk of sudden unexpected death in epilepsy (SUDEP).
SCN1A has been closely connected with a number of other voltage-gated sodium channel genes (i.e., SCN1B, SCN2A, SCN3A). These genes may contribute both pathophysiologically and phenotypically to a number of the genetic epilepsies. Moreover, phenotypic expression of these other genes can overlap with those of SCN1A. This information suggests a heterogeneous group of genetic epilepsies. Nevertheless, this important well-organized multinational study contributes a better understanding of SCN1A-related mesial temporal lobe epilepsy with hippocampal sclerosis. Moreover, it provides a systematic approach that could inevitably lead to both prognosis and potential therapies in a subgroup of children with MTLE and a history of FS.
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